About: HybriCell

An Entity of Type: vaccine, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

HybriCell is a therapeutic vaccine developed by Brazilian immunologist Jose Alexandre Barbuto. The treatment, which inhibits the division of cancer cells, is aimed at patients in later stages of kidney cancer or melanoma. The vaccine works by extracting certain leukocytes from the patient's blood and merging them with cancer cells, enabling the body to recognize and attack other similar cancer cells. In studies conducted in 2001 and 2003, 80% of test subjects showed improvement without harmful side effects. Though test groups were relatively small, the results of the studies show evidence that the drug is effective.

Property	Value
dbo:abstract	HybriCell is a therapeutic vaccine developed by Brazilian immunologist Jose Alexandre Barbuto. The treatment, which inhibits the division of cancer cells, is aimed at patients in later stages of kidney cancer or melanoma. The vaccine works by extracting certain leukocytes from the patient's blood and merging them with cancer cells, enabling the body to recognize and attack other similar cancer cells. In studies conducted in 2001 and 2003, 80% of test subjects showed improvement without harmful side effects. Though test groups were relatively small, the results of the studies show evidence that the drug is effective. (en)
dbo:alternativeName	HybriCell (en)
dbo:wikiPageID	34952645 (xsd:integer)
dbo:wikiPageLength	7016 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	977973477 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Monocyte dbr:Apheresis dbr:Cytokine dbr:Vaccine dbr:Melanoma dbr:Leukocyte dbr:Dendritic_cell dbc:Cancer_vaccines dbr:Chemotherapy dbr:Kidney_cancer dbr:Immunologist
dbp:chemspiderid	none (en)
dbp:target	melanoma, renal cancer (en)
dbp:tradename	HybriCell (en)
dbp:type	vaccine (en)
dbp:vaccineType	conjugate (en)
dbp:wikiPageUsesTemplate	dbt:As_of dbt:Cite_journal dbt:Clarify dbt:Drugbox dbt:Orphan dbt:Reflist dbt:MEDRS
dct:subject	dbc:Cancer_vaccines
gold:hypernym	dbr:Vaccine
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatCancerVaccines dbo:Vaccine yago:Antigen115037339 yago:Immunogen103562739 yago:Matter100020827 yago:PhysicalEntity100001930 dbo:Drug yago:Substance100020090 yago:Vaccine104517535
rdfs:comment	HybriCell is a therapeutic vaccine developed by Brazilian immunologist Jose Alexandre Barbuto. The treatment, which inhibits the division of cancer cells, is aimed at patients in later stages of kidney cancer or melanoma. The vaccine works by extracting certain leukocytes from the patient's blood and merging them with cancer cells, enabling the body to recognize and attack other similar cancer cells. In studies conducted in 2001 and 2003, 80% of test subjects showed improvement without harmful side effects. Though test groups were relatively small, the results of the studies show evidence that the drug is effective. (en)
rdfs:label	HybriCell (en)
owl:sameAs	freebase:HybriCell yago-res:HybriCell wikidata:HybriCell https://global.dbpedia.org/id/4nBzu
prov:wasDerivedFrom	wikipedia-en:HybriCell?oldid=977973477&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:HybriCell
is foaf:primaryTopic of	wikipedia-en:HybriCell

This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License